. These immature DCs capture antigens, and DC activation with adjuvants triggers their migration toward secondary lymphoid organs and their maturation. DCs display antigens in the context of classical major histocompatibility (MHC) class I and MHC class II molecules or in the context of nonclassical CD1 molecules, which allow the selection of rare antigen-specific T lymphocytes. If DCs do not receive maturation signals, they will remain immature and antigen presentation will lead to immune regulation and/or suppression.
DCs represent a complex system of cells that are composed of different subsets with distinct functions. Studies of human cutaneous DCs demonstrated their phenotypic and functional heterogeneity (Nestle et al., 2009 ). In particular, Langerhans cells specialize in priming CD8 + T cell immunity, whereas interstitial/dermal (CD14 + ) DCs promote humoral immunity (Klechevsky et al., 2008) . DCs express numerous nonclonal pattern recognition receptors (PRRs), which permit sensing and transmission of danger signals to adaptive immunity (Reis e Sousa, 2011). These DC properties can be harnessed to generate more efficient cancer vaccines.
Lymph Node
DCs initiate an immune response by presenting the captured antigen, which is in the form of peptide-major histocompatibility complex (MHC) molecule complexes, to naive (that is, antigen-inexperienced) T cells in lymphoid tissues. When compared with other APCs, such as macrophages, DCs are extremely efficient and can elicit very low numbers of T cells to respond, thus explaining their nickname of "professional APCs" (Lanzavecchia and Sallusto, 2001 ). Naive CD8 + T cells differentiate into CTLs in lymphoid organs upon encounter with DCs presenting tumor-derived peptides in the context of costimulation through CD80, CD70, and 4-1BB, as well as DC-derived cytokines such as IL-12 and IL-15 (Zhang and Bevan, 2011) . The priming of the new repertoire of T cells might be critical for clinical success. Naive CD4+ T cells can give rise to helper cells with distinct cytokine profiles or to regulatory T cells whose role is to dampen the immune response. T cells migrate through blood.
Tumor
Upon arrival to tumor beds, CD8 + T cells must confront numerous barriers, including: (1) intrinsic regulators, for example, CD28-CTLA-4, PD1-PDL1, and ILTs (Pardoll, 2012) , as well as extrinsic regulators cells such as Tregs or myeloid-derived suppressor cells (MDSCs); (2) a corrupted tumor microenvironment with protumor inflammation (Coussens et al., 2013) ; (3) antigen loss and immune evasion of tumor targets; and (4) tissue-specific alterations such as fatty cells in breast cancer or desmofibrosis in pancreatic cancer stroma. Killing of tumor cells either via T cells or by standard therapy can lead to endogenous antigen release and DC activation, a phenomenon called "endogenous vaccination."
Practice
DCs can be exploited for vaccination against cancer through various means, including: (1) nontargeted peptide/protein and nucleic-acid-based vaccines captured by DCs in vivo, (2) vaccines composed of antigens directly coupled to anti-DC-antibodies, or (3) vaccines composed of ex-vivo-generated DCs that are loaded with antigens.
Peptide-protein vaccines are poorly immunogenic by themselves unless adjuvants are added to generate robust antitumor immune responses. Many adjuvants are currently under evaluation as constituents of cancer vaccines.
DCs are also engaged in response to complex vaccine preparations such as GVAX tumor cell-based vaccines, in which cancer cells are genetically modified to express GM-CSF, which attracts and activates DCs (Le et al., 2012) . Another vaccine platform is based on recombinant Listeria monocytogenes (Lm), an intracellular bacterium that targets DCs in vivo and utilizes both class I and II antigen-processing pathways. The live mutant Lm-based vaccine that expresses mesothelin elicits mesothelin-specific T cells in mice and humans (Le et al., 2012) . Engineered viruses can ferry selected antigens as well as costimulation cassettes. Another strategy is based on intratumoral delivery of oncolytic viruses, i.e., viruses that preferentially infect and kill cancer cells. These can be modified to express GM-CSF to attract DCs and lymphocytes at the lysed tumor site.
DC vaccines can also be generated ex vivo, loaded with different forms of antigens, activated, and injected in patients (Steinman, 2012) . Finally, pioneering studies from Ralph Steinman and Michel Nussenzweig demonstrated the principle of targeting antigens to DCs in vivo through the coupling of antigens to antibodies specific to DC surface receptors such as DEC205 or DCIR (Bonifaz et al., 2002) . Importantly, in the absence of adjuvants, targeting antigens to DEC205 + DCs in vivo induces antigen-specific tolerance, which can be used as treatment against autoimmune diseases such as type I diabetes (Steinman, 2012) . Administration of these complex vaccines with DC-activators such as TLR3, TLR7-8, or CD40 agonists enables the maturation of DCs and thus the establishment of immunity rather than tolerance (Steinman, 2012) .
